Roman Galetto, PhD, Cellectis, Paris, France, briefly discusses some novel allogeneic chimeric antigen receptor T-cell (CAR-T) therapies being developed for the treatment of various hematological indications, including B-cell acute lymphoblastic leukemia (B-ALL), acute myeloid leukemia (AML), multiple myeloma, and other B-cell malignancies. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.